SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics is filing a preliminary prospectus supplement for a…

Tango Therapeutics, Inc. · 424B5 filed Jun 8, 2026 at 16:16 ET

At the news

BEARISHIMPACT 7/10

424B5 filed Jun 8, 2026 at 16:16 ET

Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $75M underwriter option. The filing comes on the same day the company reported strikingly positive early Phase 1/2 clinical data for vopimetostat + daraxonrasib in MTAP-deleted/RAS-mutant pancreatic cancer (92% ORR, 90% 6-mo PFS in PDAC), which it plans to advance to Phase 3. The large equity raise creates immediate and substantial dilution (~$2.72 tangible book value per share vs. $20.22 stock price), and the preliminary nature of the filing (many terms still blank) signals the offering price is not yet set, the stock may trade down on the surprise dilutive capital need despite the positive clinical readout.

  • Tango is offering $500M of common stock via a 424B5 shelf takedown (preliminary prospectus supplement dated June 8, 2026)
  • Underwriters have a 30-day option to purchase up to an additional $75M in shares
  • Last sale price on June 5, 2026 was $20.22 per share; company had $2.9B market cap
  • Net tangible book value as of March 31, 2026 was ~$391.5M, or $2.72 per share, new investors will face immediate and substantial dilution

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access